Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Chinese participants with obesity or overweight
NCT06916091Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Eloralintide with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events and Serious Adverse Events at 10 weeks. Started Apr 2025; status: completed.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06916091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916091.